New trial
Phase 3 trial: Belrestotug (TIGIT mAb) plus Dostarlimab (PD-1 inhibitor) in PD-L1 high NSCLC.
- Trial ID
- NCT06472076 on ClinicalTrials.gov
- Cancer type
- Lung Cancer (NSCLC, pan-lung)
- Stage of research
- Registrational
- Location
- 188 Locations
- Published in
- New in Oncology - June 23, 2025
This randomized, multicenter, double‑blind study compares belrestotug, a TIGIT monoclonal antibody, and dostarlimab, a PD‑1 inhibitor, versus pembrolizumab plus placebo for first‑line treatment of unresectable, locally advanced or metastatic PD‑L1 high NSCLC. The trial evaluates progression‑free and overall survival and is sponsored by GlaxoSmithKline.
More in non-small cell lung cancer
-
Trial result · Oct 22, 2026 · NCT04905316
Canakinumab (IL-1β blockade) + cCRT and durvalumab consolidation hits 67% 24-mo PFS in unresectable stage III NSCLC -
Trial result · Oct 15, 2026 · NCT04495153
CAN-2409 + valacyclovir reports 14.3-month median OS in treated NSCLC patients; 24.5 months in a selected per-protocol group -
New trial · Oct 15, 2026 · NCT07852247
Phase 1 CyberKnife SBRT uses Synchrony respiratory motion tracking for ultra-central NSCLC -
New trial · Oct 15, 2026 · NCT07617337
Phase 1 AQUA07 allosteric ALK inhibitor (macrocyclic peptide) alone or with lorlatinib in ALK-positive NSCLC -
Trial result · Oct 8, 2026 · NCT03052608
AI volumetric brain-met response may better predict PFS in ALK+ NSCLC